Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT04463771 |
| Title | Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. (POD1UM-204) |
| Acronym | POD1UM-204 |
| Recruitment | Active, not recruiting |
| Gender | female |
| Phase | Phase II |
| Variant Requirements | Yes |
| Sponsors | Incyte Corporation |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | ITA | GRC | FRA | DEU | BEL |
CKB BOOST